Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BCKDK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BCKDK Recombinant Protein (WT, Mutant, Mito-Peptide Truncated Active). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. | View BCKDK Products |
| Gene Delivery | BCKDK Promise-ORF / Lentivirus. Full-length ORF for stable cell line generation and cellular metabolic profiling. | View BCKDK Products |
| Benchmark Ab | Anti-BCKDK Recombinant/Monoclonal Antibody. Sequence-verified positive control for SPR, ELISA, and western blot. | View BCKDK Products |
| Validator | BCKDK siRNA Set. For knockdown verification in BCAA metabolism and cellular flux assays. | View BCKDK Products |
| Related Target A | BCAT2. Synergistic BCAA catabolic enzyme upstream of BCKDH complex. | View BCAT2 Products |
| Related Target B | PPM1K (PP2Cm). Mitochondrial phosphatase and direct functional counter-regulator of BCKDK. | View PPM1K Products |
| Related Target C | BCKDHA. Canonical substrate E1 alpha subunit; essential for in vitro enzymatic phosphorylation and kinase selectivity screening. | View BCKDHA Products |
| Related Target D | ACLY. ATP-citrate lyase; direct non-canonical phosphorylation substrate of BCKDK driving oncogenic lipogenesis in solid tumors. | View ACLY Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity & Off-target Profiling (PDK family, mitochondrial kinases) | High-purity BCKDK & PDK ortholog proteins available with >95% purity; Sequence Verified by Mass Spec. |
| Active Site vs. Allosteric Mechanism Determination | BCKDK Mutant Panel (ATP-binding & allosteric variants) as recombinant proteins for mechanistic deconvolution. |
| Cell-Based Target Engagement & BCAA Metabolism Modulation | BCKDK Lentivirus Particles (Endotoxin Controlled) for stable transduction and functional rescue studies. |
| Lack of Assay Controls & Specificity Verification | Benchmark Anti-BCKDK Antibody + Validated siRNA included for orthogonal target confirmation. |
| Mitochondrial Transit Peptide Aggregation | N-terminal truncated mature active BCKDK enzyme expressed with native folding and >95% purity verified by SDS-PAGE and SEC. |
| Counter-Screening Against Atypical Kinases | Homolog panel including structural relatives (PDHK1, PDHK2, PDHK3, PDHK4) strictly sequence-verified for off-target selectivity assays. |
| Lack of Substrate Specificity Controls | High-purity recombinant BCKDHA and ACLY substrate proteins available for ADP-Glo and LC-MS phosphorylation kinetics. |
| False Positives in Cellular Phenotyping | Sequence-verified siRNA panels included to confirm specific BCKDK-dependent metabolic flux alteration. |
Live BCKDK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BCKDK (Branched-Chain Ketoacid Dehydrogenase Kinase) therapeutics is intensifying as researchers uncover its critical dual role in systemic metabolic regulation and oncogenic signaling. Historically recognized as the negative regulator of branched-chain amino acid (BCAA) catabolism, BCKDK inhibition is emerging as a novel approach to treat insulin resistance, Type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), and heart failure. Expansion into rare metabolic indications such as Maple Syrup Urine Disease (MSUD) and heart failure with preserved ejection fraction (HFpEF) is expected to diversify the indication portfolio beyond Type 2 diabetes and sarcopenia. Simultaneously, the discovery that BCKDK directly phosphorylates and activates ATP-citrate lyase (ACLY) outside the mitochondrial matrix has shifted oncology R&D toward targeting BCKDK to starve tumors of de novo lipogenesis and suppress RAS/MEK/ERK signaling. As early-stage small-molecule inhibitors transition from tool compounds (such as BT2) toward highly selective, orally bioavailable clinical candidates, the next wave of drug development focuses on achieving absolute structural selectivity over the structurally related pyruvate dehydrogenase kinase (PDHK) family.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Pfizer, Academic Consortia (e.g., UT Southwestern) | MASH, Type 2 Diabetes, Heart Failure | Kinase Activity & Selectivity Assay (Need active BCKDK & PDHK counter-screen proteins) |
| Small Molecule (ATP-Competitive) | AstraZeneca, Early Biotechs | Colorectal Cancer, Glioblastoma, Pancreatic Cancer | Substrate Phosphorylation Assay (Need high-purity ACLY & BCKDHA substrates) |
| Gene Regulation (siRNA/ASO) | Rare disease gene therapy specialists | MSUD | Target Engagement Assay (Need BCKDK ORF Lentivirus for rescue & knockdown correlation) |
| Targeted Protein Degradation (PROTAC) | Emerging Biotech Pipelines | Refractory Solid Tumors with BCKDK Amplification | Ternary Complex & Target Engagement Validation (Need sequence-verified active protein & benchmark antibodies) |